Post by Drug Development & Delivery

Lonza is making significant strides in the CDMO landscape by expanding its payload-linker manufacturing capacity at the Visp site, reinforcing its leadership in the ADC arena. This expansion aims to meet the growing demand for complex HPAPIs and ADC payload-linkers by introducing new commercial-scale capabilities. With ADCs being a fast-growing segment, this move positions Lonza to better serve the increasing need for specialized synthesis and purification technologies. The new facility promises to support both clinical and commercial programs, accelerating the development of groundbreaking ADC therapies. As a result, Lonza's commitment to advancing therapeutic innovations is stronger than ever, potentially delivering life-changing treatments to patients. #PharmaceuticalInnovation #ADCTherapies #DrugDevelopment #Lonza #HealthcareInnovation